<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2020-26-5-509-517</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-2038</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Статины: неожиданная помощь при COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Statins: unexpected help in COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1874-8661</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гареева</surname><given-names>Д. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Gareeva</surname><given-names>D. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гареева Диана Фирдависовна — кандидат медицинских наук, врач-кардиолог, ассистент кафедры пропедевтики внутренних болезней</p><p>ул. Ленина, д. 3, г. Уфа, 450008</p></bio><bio xml:lang="en"><p>Diana F. Gareeva, MD, PhD, Assistant, Department of Propaedeutics of Internal Diseases, Cardiologist</p><p>3 Lenin street, Ufa, 450008</p></bio><email xlink:type="simple">danika09@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9927-6626</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусин</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Musin</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мусин Тимур Ильгамович — врач-кардиолог, аспирант кафедры пропедевтики внутренних болезней</p><p>Уфа</p></bio><bio xml:lang="en"><p>Timur I. Musin, MD, Cardiologist, PhD Student, Department of Internal Diseases Propedaeutics</p><p>Ufa</p></bio><email xlink:type="simple">tyrannyah@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2125-4897</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлов Валентин Николаевич — доктор медицинских наук, профессор, член-корреспондент РАН, ректор</p><p>Уфа</p></bio><bio xml:lang="en"><p>Valentin N. Pavlov, MD, PhD, DSc, Professor, Head, Urology Department</p><p>Ufa</p></bio><email xlink:type="simple">pavlov@bashgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5972-6418</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давтян</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Davtyan</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Давтян Паруйр Артакович — ординатор кафедры пропедевтики внутренних болезней</p><p>Уфа</p></bio><bio xml:lang="en"><p>Paruyr A. Davtyan, MD, Resident, Department of Internal Diseases Propedaeutics</p><p>Ufa</p></bio><email xlink:type="simple">davtyanparuir@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5527-4477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ишметов</surname><given-names>В. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Ishmetov</surname><given-names>V. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ишметов Владимир Шамилевич — доктор медицинских наук, заведующий отделением сердечно-сосудистой и рентгенохирургии клиники</p><p>Уфа</p></bio><bio xml:lang="en"><p>Vladimir Sh. Ishmetov, MD, PhD, DSc, Head, Department of Cardiovascular and X-ray Surgery, Clinic</p><p>Ufa</p></bio><email xlink:type="simple">ishv75@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9627-5508</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотникова</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikova</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Плотникова Марина Раилевна — кандидат медицинских наук, заведующая отделением кардиологии клиники</p><p>Уфа</p></bio><bio xml:lang="en"><p>Marina R. Plotnikova, MD, PhD, Head, Cardiology Department</p><p>Ufa</p></bio><email xlink:type="simple">plotnikovam.r@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9455-1801</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлов Алексей Валерьевич — кандидат медицинских наук, заведующий отделением кардиохирургии клиники</p><p>Уфа</p></bio><bio xml:lang="en"><p>Aleksey V. Pavlov, MD, PhD, Head, Department of Cardiac Surgery</p><p>Ufa</p></bio><email xlink:type="simple">docpavlov1976@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6342-4930</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кай</surname><given-names>Бенжи</given-names></name><name name-style="western" xml:lang="en"><surname>Cai</surname><given-names>Benzhi</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кай Бенжи — профессор кафедры фармакологии при Китайской государственной ведущей лаборатории по биомедицине/фармацевтике, при Китайской государственной ведущей лаборатории по изучению сердечно-сосудистых заболеваний, Фармацевтический колледж</p><p>Харбин</p></bio><bio xml:lang="en"><p>Benzhi Cai, Professor, Department of Pharmacology (the State-Province Key Laboratories of Biomedicine-Pharmaceutics, China Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy</p><p>Harbin</p></bio><email xlink:type="simple">caibz@ems.hrbmu.edu.cn</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2582-137X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стрикер</surname><given-names>П.</given-names></name><name name-style="western" xml:lang="en"><surname>Stricker</surname><given-names>P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Стрикер Присцила Элиас Феррейра — аспирант кафедры регенеративной медицины, клеточной терапии и биотехнологий</p><p>Куритиба</p></bio><bio xml:lang="en"><p>P. Stricker, MSc, PhD Student, Cell Therapy and Biotechnology in Regenerative Medicine Department</p><p>Curitiba</p></bio><email xlink:type="simple">priscilaeferreira@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4860-2855</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карвальо</surname><given-names>К.</given-names></name><name name-style="western" xml:lang="en"><surname>Carvalho</surname><given-names>K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Де Карвальо Катрин Атаиде Тейсейра — профессор кафедры Исследовательского института и регенеративной медицины, клеточной терапии и биотехнологий</p><p>Куритиба</p></bio><bio xml:lang="en"><p>K. Carvalho, MD, MsC, PhD, Professor, Cell Therapy and Biotechnology in Regenerative Medicine Department</p><p>Curitiba</p></bio><email xlink:type="simple">katherinecarv@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2386-6707</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загидуллин</surname><given-names>Н. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagidullin</surname><given-names>N. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загидуллин Науфаль Шамилевич — доктор медицинских наук, профессор, директор научно-исследовательского института «Кардиология», заведующий кафедрой пропедевтики внутренних болезней</p><p>Уфа</p></bio><bio xml:lang="en"><p>Naufal Sh. Zagidullin, MD, PhD, DSc, Professor, Director, Research Institute of Cardiology, Head, Department of Propaedeutics of Internal Diseases</p><p>Ufa</p></bio><email xlink:type="simple">znaufal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное образовательное учреждение высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Харбинский медицинский университет</institution><country>Китай</country></aff><aff xml:lang="en"><institution>Harbin Medical University</institution><country>China</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Исследовательский институт Пеле Пекено Принсипи и факультет Пекено Принсипи</institution><country>Бразилия</country></aff><aff xml:lang="en"><institution>Pelé Pequeno Príncipe Research Institute and Pequeno Príncipe Faculty</institution><country>Brazil</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2020</year></pub-date><volume>26</volume><issue>5</issue><fpage>509</fpage><lpage>517</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гареева Д.Ф., Мусин Т.И., Павлов В.Н., Давтян П.А., Ишметов В.Ш., Плотникова М.Р., Павлов А.В., Кай Б., Стрикер П., Карвальо К., Загидуллин Н.Ш., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Гареева Д.Ф., Мусин Т.И., Павлов В.Н., Давтян П.А., Ишметов В.Ш., Плотникова М.Р., Павлов А.В., Кай Б., Стрикер П., Карвальо К., Загидуллин Н.Ш.</copyright-holder><copyright-holder xml:lang="en">Gareeva D.F., Musin T.I., Pavlov V.N., Davtyan P.A., Ishmetov V.S., Plotnikova M.R., Pavlov A.V., Cai B., Stricker P., Carvalho K., Zagidullin N.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/2038">https://htn.almazovcentre.ru/jour/article/view/2038</self-uri><abstract><p>Пандемия COVID-19 оказала беспрецедентное воздействие на здоровье миллионов людей во всем мире. К сожалению, затягивается процесс создания эффективных противовирусных препаратов и вакцины. Поэтому исследуются уже имеющиеся в наличии лекарственные препараты, которые могут оказать эффект при COVID-19. В связи с тем, что вирусная инфекция часто поражает сердечно-сосудистую систему, вызывая инфаркты миокарда, вирусные миокардиты, тахиаритмии и стрессовые кардиомиопатии, была выдвинута теория, что ингибиторы 3-гидрокси-3-метилглютарил-кофермент А редуктазы (ГМГКоА-редуктазы) — статины — способны снизить риск развития сердечно-сосудистых осложнений. В последние годы данный класс препаратов был предложен в том числе при вирусных инфекциях, таких как вирус гриппа или MERS-CoV. В обзоре обсуждаются как последние клинические данные об эффективности статинов при COVID-19, так и их плейотропные механизмы, способные ограничить патогенное действие вирусов на организм. В частности, статины могут действовать на липидные клеточные рафты (субдоменов плазматической мембраны), снижая в них концентрацию липидов; ограничивать взаимодействие вируса с рецепторами ангиотензинпревращающего фермента-2 и CD-147; обладают противовоспалительным эффектом (блокировка молекулярных механизмов воспаления, включая NF-κB и NLRP3); ограничивают развитие «цитокинового шторма» у тяжелых пациентов с COVID-19; могут ингибировать основную протеазу SARS-CoV-2, влиять на коагуляцию, ограничивать симпатическую активность нервной системы и так далее. В двух крупных когортных наблюдательных исследованиях (96032 и 13981 больных) у госпитализированных пациентов с COVID-19, принимающих статины, было показано снижение внутрибольничной смертности и смертности через 28 дней после начала госпитализации. Таким образом, данная группа препаратов может занять свое место в лечении COVID-19.</p></abstract><trans-abstract xml:lang="en"><p>The COVID-19 pandemic has had a huge impact on the health of millions of people around the world on an unprecedented scale. Unfortunately, the process of creating effective antiviral drugs and vaccines is being delayed. Therefore, drugs that are already available and may have an effect on COVID-19 are being investigated. Due to the fact that viral infection often affects the cardiovascular system, causing myocardial infarction, viral myocarditis, tachyarrhythmias and stress cardiomyopathies, a theory was put forward that HMG-CoA reductase (3-hydroxy-3methyl-glutaryl-CoA reductase) inhibitors (statins) can reduce the risk of cardiovascular complications in these patients. In recent years, this class of drugs has been proposed, including for viral infections, such as the influenza virus or MERS-CoV. The review discusses both the latest clinical data on the efficacy of statins in COVID-19 and the pleotropic mechanisms of statins that can limit the pathogenic effect of viruses. In particular, statins can act on lipid cell rafts (subdomains of the plasma membrane), decreasing their lipid concentration; limiting the interaction of the virus with the receptors of angiotensin-converting enzyme-2 and CD-147. Statins have an antiinflammatory effect (blocking the molecular mechanisms of inflammation, including NF-κB and NLRP3), limit the development of a “cytokine storm” in severe patients with COVID-19; can inhibit SARS-CoV-2 basic protease; influence coagulation, limit sympathetic activity and have other effects. In two large cohort observational studies (n = 96032 and n = 13981), hospitalized patients with COVID-19 who were taking statins showed a decrease in hospital mortality and mortality 28 days after the admission to the hospital. Thus, statins can play a role in the treatment of COVID-19.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>статины</kwd><kwd>плейотропные эффекты</kwd><kwd>COVID-19</kwd><kwd>ангиотензинпревращающий фермент 2</kwd><kwd>CD 149</kwd><kwd>смертность</kwd><kwd>липидные рафты</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>statins</kwd><kwd>pleotropic effects</kwd><kwd>COVID-19</kwd><kwd>angiotensin-converting enzyme 2</kwd><kwd>CD 147</kwd><kwd>mortality</kwd><kwd>lipid rafts</kwd><kwd>inflammation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dolinski D, Dolinska B, Zmaczynska-Witek B, Banach M, Kulesza W. Unrealistic optimism in the time of coronavirus pandemic: may it help to kill, if so-whom: disease or the person? J Clin Med. 2020;9(5):1464. doi:10.3390/jcm9051464</mixed-citation><mixed-citation xml:lang="en">Dolinski D, Dolinska B, Zmaczynska-Witek B, Banach M, Kulesza W. Unrealistic optimism in the time of coronavirus pandemic: may it help to kill, if so-whom: disease or the person? J Clin Med. 2020;9(5):1464. doi:10.3390/jcm9051464</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in relation to COVID-19: should we care about it? J Clin Med. 2020;9(6):1909. doi:10.3390/jcm9061909</mixed-citation><mixed-citation xml:lang="en">Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in relation to COVID-19: should we care about it? J Clin Med. 2020;9(6):1909. doi:10.3390/jcm9061909</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. doi:10.1146/annurev.pharmtox.45.120403.095748</mixed-citation><mixed-citation xml:lang="en">Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. doi:10.1146/annurev.pharmtox.45.120403.095748</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigues Diez R, Rodrigues-Diez R, Lavoz C, RayegoMateos S, Civantos E, Rodriguez-Vita J et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One. 2010;5(11):e14145. doi:10.1371/journal.pone.0014145</mixed-citation><mixed-citation xml:lang="en">Rodrigues Diez R, Rodrigues-Diez R, Lavoz C, RayegoMateos S, Civantos E, Rodriguez-Vita J et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One. 2010;5(11):e14145. doi:10.1371/journal.pone.0014145</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–8. doi:10.1001/jamacardio.2020.1017</mixed-citation><mixed-citation xml:lang="en">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–8. doi:10.1001/jamacardio.2020.1017</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci. 2020;16(3):485–489. doi:10.5114/aoms.2020.94503</mixed-citation><mixed-citation xml:lang="en">Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci. 2020;16(3):485–489. doi:10.5114/aoms.2020.94503</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020]. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140–6736(20)30183–5</mixed-citation><mixed-citation xml:lang="en">Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020]. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140–6736(20)30183–5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China [published online ahead of print, 2020]. JAMA Cardiol. 2020;5(7):802–810. doi:10.1001/jamacardio.2020.0950</mixed-citation><mixed-citation xml:lang="en">Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China [published online ahead of print, 2020]. JAMA Cardiol. 2020;5(7):802–810. doi:10.1001/jamacardio.2020.0950</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Yu Y, Xu J, Shu H, an Xia J, Liu H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020;8(4): e26]. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5</mixed-citation><mixed-citation xml:lang="en">Yang X, Yu Y, Xu J, Shu H, an Xia J, Liu H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020;8(4): e26]. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Загидуллин Н. Ш., Гареева Д. Ф., Ишметов В. Ш., Павлов А. В., Плотниковa М. Р., Пушкарева А. Э. и др. Ренин-ангиотензиновая система при новой коронавирусной инфекции COVID-2019. Артериальная гипертензия. 2020;26(3):240–247. doi:10.18705/1607-419X-2020-26-3-240-247.</mixed-citation><mixed-citation xml:lang="en">Zagidullin NS, Gareeva DF, Ishmetov VS, Pavlov AV, Plotnikova MR, Pushkareva AE et al. Renin-angiotensin-aldosterone system in new coronavirus infection 2019. Arterial’naya Gipertenziya = Arterial Hypertension. 2020;26(3):240–247. doi:10.18705/1607419X-2020-26-3-240-247. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID - 19) with myocardial injury and mortality [published online ahead of print, 2020]. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1105</mixed-citation><mixed-citation xml:lang="en">Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID - 19) with myocardial injury and mortality [published online ahead of print, 2020]. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1105</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):258–259. doi:10.1093/ehjcvp/pvaa042</mixed-citation><mixed-citation xml:lang="en">Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):258–259. doi:10.1093/ehjcvp/pvaa042</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pirro M, Simental-Mendía LE, Bianconi V, Watts GF, Banach M, Sahebkar A. Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: a systematic review and veta-analysis of interventional studies. J Clin Med. 2019;8(1):118. Published 2019. doi:10.3390/jcm8010118</mixed-citation><mixed-citation xml:lang="en">Pirro M, Simental-Mendía LE, Bianconi V, Watts GF, Banach M, Sahebkar A. Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: a systematic review and veta-analysis of interventional studies. J Clin Med. 2019;8(1):118. Published 2019. doi:10.3390/jcm8010118</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–238. doi:10.1016/j.phrs.2018.08.014</mixed-citation><mixed-citation xml:lang="en">Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–238. doi:10.1016/j.phrs.2018.08.014</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ. 2012;184(7):E 367–E 372. doi:10.1503/cmaj.111017</mixed-citation><mixed-citation xml:lang="en">Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ. 2012;184(7):E 367–E 372. doi:10.1503/cmaj.111017</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43(2):199–205. doi:10.1086/505116</mixed-citation><mixed-citation xml:lang="en">Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43(2):199–205. doi:10.1086/505116</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight [published online ahead of print, 2020]. Drug Dev Res. 2020;81(5):541–543. doi:10.1002/ddr.21666</mixed-citation><mixed-citation xml:lang="en">Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight [published online ahead of print, 2020]. Drug Dev Res. 2020;81(5):541–543. doi:10.1002/ddr.21666</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419–423. doi:10.1080/08998280.2018.1499293</mixed-citation><mixed-citation xml:lang="en">Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419–423. doi:10.1080/08998280.2018.1499293</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125(11):1111–1123. doi:10.1016/j.amjmed.2012.04.011</mixed-citation><mixed-citation xml:lang="en">Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125(11):1111–1123. doi:10.1016/j.amjmed.2012.04.011</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med. 2011;39(11):2440–2446. doi:10.1097/CCM.0b013e318225742c</mixed-citation><mixed-citation xml:lang="en">Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med. 2011;39(11):2440–2446. doi:10.1097/CCM.0b013e318225742c</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;2014:872370. doi:10.1155/2014/872370</mixed-citation><mixed-citation xml:lang="en">Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;2014:872370. doi:10.1155/2014/872370</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Fulcheri E et al. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Acta Biomed. 2020;91(1):161–164. doi:10.23750/abm.v91i1.9402</mixed-citation><mixed-citation xml:lang="en">Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Fulcheri E et al. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Acta Biomed. 2020;91(1):161–164. doi:10.23750/abm.v91i1.9402</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Choi KS, Aizaki H, Lai MM. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol. 2005;79(15):9862–9871. doi:10.1128/JVI.79.15.98629871.2005</mixed-citation><mixed-citation xml:lang="en">Choi KS, Aizaki H, Lai MM. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol. 2005;79(15):9862–9871. doi:10.1128/JVI.79.15.98629871.2005</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011;19(7):368–375. doi:10.1016/j.tim.2011.03.007</mixed-citation><mixed-citation xml:lang="en">Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011;19(7):368–375. doi:10.1016/j.tim.2011.03.007</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon JH, Lee C. Cholesterol is important for the entry process of porcine deltacoronavirus. Arch Virol. 2018;163(11):31193124. doi:10.1007/s00705-018-3967-7</mixed-citation><mixed-citation xml:lang="en">Jeon JH, Lee C. Cholesterol is important for the entry process of porcine deltacoronavirus. Arch Virol. 2018;163(11):31193124. doi:10.1007/s00705-018-3967-7</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARSCoV entry into Vero E 6 cells. Biochem Biophys Res Commun. 2008;369(2):344–349. doi:10.1016/j.bbrc.2008.02.023</mixed-citation><mixed-citation xml:lang="en">Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARSCoV entry into Vero E 6 cells. Biochem Biophys Res Commun. 2008;369(2):344–349. doi:10.1016/j.bbrc.2008.02.023</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hu X, Chen D, Wu L, He G, Ye W. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. [Published online ahead of print 21 February 2020]. doi:10.2139/ssrn.3544826.</mixed-citation><mixed-citation xml:lang="en">Hu X, Chen D, Wu L, He G, Ye W. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. [Published online ahead of print 21 February 2020]. doi:10.2139/ssrn.3544826.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9(1):96–102. doi:10.1016/j.micinf.2006.10.015</mixed-citation><mixed-citation xml:lang="en">Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9(1):96–102. doi:10.1016/j.micinf.2006.10.015</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol. 2006;177(10):7416–7422. doi:10.4049/jimmunol.177.10.7416</mixed-citation><mixed-citation xml:lang="en">Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol. 2006;177(10):7416–7422. doi:10.4049/jimmunol.177.10.7416</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al. A crucial role of angiotensin converting enzyme 2 (ACE 2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267</mixed-citation><mixed-citation xml:lang="en">Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al. A crucial role of angiotensin converting enzyme 2 (ACE 2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828. doi:10.1038/nature00786</mixed-citation><mixed-citation xml:lang="en">Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828. doi:10.1038/nature00786</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi:10.1038/nature03712</mixed-citation><mixed-citation xml:lang="en">Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi:10.1038/nature03712</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE 2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134020-05985-9</mixed-citation><mixed-citation xml:lang="en">Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE 2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134020-05985-9</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">South AM, Diz DI, Chappell MC. COVID-19, ACE 2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084–H1090. doi:10.1152/ajpheart.00217.2020</mixed-citation><mixed-citation xml:lang="en">South AM, Diz DI, Chappell MC. COVID-19, ACE 2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084–H1090. doi:10.1152/ajpheart.00217.2020</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K, Chen W, Zhou Y, Lian J, Zhang Z, Du P et al. SARS-CoV-2 invades host cells via a novel route: CD 147-spike protein. bioRxiv. 2020.03.14.988345. [Published online ahead of print 14 March 2020]. doi:10.1101/2020.03.14.988345</mixed-citation><mixed-citation xml:lang="en">Wang K, Chen W, Zhou Y, Lian J, Zhang Z, Du P et al. SARS-CoV-2 invades host cells via a novel route: CD 147-spike protein. bioRxiv. 2020.03.14.988345. [Published online ahead of print 14 March 2020]. doi:10.1101/2020.03.14.988345</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Liang X, Yang LX, Guo R, Shi Y, Hou X, Yang Z et al. Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE 2 pathway. Exp Ther Med. 2017;13(3):835–844. doi:10.3892/etm.2017.4062</mixed-citation><mixed-citation xml:lang="en">Liang X, Yang LX, Guo R, Shi Y, Hou X, Yang Z et al. Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE 2 pathway. Exp Ther Med. 2017;13(3):835–844. doi:10.3892/etm.2017.4062</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001;286(1):64–70. doi:10.1001/jama.286.1.64</mixed-citation><mixed-citation xml:lang="en">Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001;286(1):64–70. doi:10.1001/jama.286.1.64</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ortego M, Gómez-Hernández A, Vidal C, SánchezGalán E, Blanco-Colio LM, Martín-Ventura JL et al. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol. 2005;45(5):468–475. doi:10.1097/01.fjc.0000159042.50488.e5</mixed-citation><mixed-citation xml:lang="en">Ortego M, Gómez-Hernández A, Vidal C, SánchezGalán E, Blanco-Colio LM, Martín-Ventura JL et al. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol. 2005;45(5):468–475. doi:10.1097/01.fjc.0000159042.50488.e5</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Parsamanesh N, Moossavi M, Bahrami A, Fereidouni M, Barreto G, Sahebkar A. NLRP3 inflammasome as a treatment target in atherosclerosis: a focus on statin therapy. Int Immunopharmacol. 2019;73:146–155. doi:10.1016/j.intimp.2019.05.006</mixed-citation><mixed-citation xml:lang="en">Parsamanesh N, Moossavi M, Bahrami A, Fereidouni M, Barreto G, Sahebkar A. NLRP3 inflammasome as a treatment target in atherosclerosis: a focus on statin therapy. Int Immunopharmacol. 2019;73:146–155. doi:10.1016/j.intimp.2019.05.006</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. 2015;26(5):409–421. doi:10.1097/MCA.0000000000000255</mixed-citation><mixed-citation xml:lang="en">Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. 2015;26(5):409–421. doi:10.1097/MCA.0000000000000255</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123(17):26052613. doi:10.1182/blood-2013-09-526277</mixed-citation><mixed-citation xml:lang="en">Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123(17):26052613. doi:10.1182/blood-2013-09-526277</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1–10. doi:10.1038/modpathol.3800247</mixed-citation><mixed-citation xml:lang="en">Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1–10. doi:10.1038/modpathol.3800247</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000</mixed-citation><mixed-citation xml:lang="en">Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Panes O, González C, Hidalgo P, Valderas JP, Acevedo M, Contreras S et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis. 2017;257: 164–171. doi:10.1016/j.atherosclerosis.2016.12.019</mixed-citation><mixed-citation xml:lang="en">Panes O, González C, Hidalgo P, Valderas JP, Acevedo M, Contreras S et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis. 2017;257: 164–171. doi:10.1016/j.atherosclerosis.2016.12.019</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020] [retracted in: Lancet. 2020]. Lancet. 2020; S 0140–6736(20)31180–6. doi:10.1016/S01406736(20)31180-6</mixed-citation><mixed-citation xml:lang="en">Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020] [retracted in: Lancet. 2020]. Lancet. 2020; S 0140–6736(20)31180–6. doi:10.1016/S01406736(20)31180-6</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 [published online ahead of print, 2020]. Cell Metab. 2020; S 1550–4131(20)30316–8. doi:10.1016/j.cmet.2020.06.015</mixed-citation><mixed-citation xml:lang="en">Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 [published online ahead of print, 2020]. Cell Metab. 2020; S 1550–4131(20)30316–8. doi:10.1016/j.cmet.2020.06.015</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigues-Diez RR, Tejera-Muñoz A, MarquezExposito L et al. Statins: Could an old friend help in the fight against COVID-19? [published online ahead of print, 2020]. Br J Pharmacol. 2020;10.1111/bph.15166. doi:10.1111/bph.15166</mixed-citation><mixed-citation xml:lang="en">Rodrigues-Diez RR, Tejera-Muñoz A, MarquezExposito L et al. Statins: Could an old friend help in the fight against COVID-19? [published online ahead of print, 2020]. Br J Pharmacol. 2020;10.1111/bph.15166. doi:10.1111/bph.15166</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Загидуллин Н. Ш., Michels G., Загидуллин Ш. З. Статины и их антиаритмическая активность. Кардиоваскулярная терапия и профилактика. 2007;6(8):116–121.</mixed-citation><mixed-citation xml:lang="en">Zagidullin NS, Michels G, Zagidullin SZ. Statins and their antiarrhythmic activity. Cardiovasc Ther Prev. 2007;6(8):116–121. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. doi:10.5114/aoms.2020.94655</mixed-citation><mixed-citation xml:lang="en">Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. doi:10.5114/aoms.2020.94655</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
